Klaus
Elenius
Professor, Institute of Biomedicine
Director, BioCity Turku
Turku Bioscience Centre
MD, PhD, professor
Research
ACTIONABLE RECEPTOR TYROSINE KINASE SIGNALING
Our goal is to understand how receptor tyrosine kinases (RTK) regulate the pathogenesis of human diseases, such as cancer. This information is needed for the development of molecularly targeted therapies. To recognize aberrations of RTK signaling in diseased tissue our laboratory also works on the molecular mechanism by which RTKs control normal processes, such as embryonic development. The work mainly focuses on the ErbB family of RTKs. Our laboratory has contributed to the field by e.g. by characterizing novel RTK signaling mechanisms, by identifying novel ErbB4 isoforms, and by determining the role of ErbBs and their ligands in angiogenesis.
Current topics
- Screens for predictive RTK mutations
- Novel RTK signaling mechanisms
- Development of preclinical models for development novel RTK inhibitors
- Sequencing of RTK inhibitor drug administration with cytotoxic agents
- In vitro “basket trials” with ErbB inhibitor drugs
- RTK signaling in angiogenesis and cardiovascular diseases
- RTKs in pediatric malignancies
- Biological role of novel ErbB4 isoforms in diseases and development
Elenius Lab members
- Anne Jokilammi, PhD
- Elli Narvi, PhD
- Deepankar Chakroborty, MSc
- Juho Heliste, MD
- Marika Koivu, MSc
- Johannes Merilahti, MSc
- Veera Ojala, MSc
- Janne Nordberg, MD
- Fred Saarinen, MSc
- Katri Vaparanta, MSc
- Kaisa Aalto, BM
- Maria Helkkula, BM
- Matias Mäenpää, BM
- Peppi Kirjalainen, BM
- Jori Torkkila, BM
Publications
Identification of Predictive ERBB Mutations by Leveraging Publicly Available Cell Line Databases (2021)
Molecular Cancer Therapeutics
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Therapeutic Potential of Targeting the SUMO Pathway in Cancer (2021)
Cancers
(Vertaisarvioitu katsausartikkeli tieteellisessä aikakauslehdessä (A2))
ANGPTL8 protein-truncating variant associated with lower serum triglycerides and risk of coronary disease (2021)
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))Genome-wide meta-analysis identifies 127 open-angle glaucoma loci with consistent effect across ancestries (2021)
Nature Communications
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Trans-biobank analysis with 676,000 individuals elucidates the association of polygenic risk scores of complex traits with human lifespan (2020)
Nature Medicine
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
The role of polygenic risk and susceptibility genes in breast cancer over the course of life (2020)
Nature Communications
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation (2020)
Journal of Visualized Experiments
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Inherited myeloproliferative neoplasm risk affects haematopoietic stem cells (2020)
Nature
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers (2020)
Nature Medicine
(Vertaisarvioitu alkuperäisartikkeli tai data-artikkeli tieteellisessä aikakauslehdessä (A1))
Suomen Lääketieteen Säätiö on kulkenut lääketieteen tutkimuksen rinnalla jo 60 vuotta (2020)
Duodecim
(Artikkeli ammattilehdessä tai kirjoitus ammatillisessa blogissa (D1))